The financials
Protagonist Therapeutics, Inc. by the numbers
Protagonist Therapeutics, Inc. (PTGX) reported revenue of $213M in Q2 2026 (quarter ended June 30, 2026), up 3749% from the same quarter a year earlier. That came with net income of $163M (76% of revenue). For the full year FY2025, revenue was $46M (−89% year on year) and net income −$130M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $213M | $5.5M | +3749% |
| Operating income | $159M | −$42M | to a profit |
| Net income | $163M | −$35M | to a profit |
| Diluted EPS | $2.29 | −$0.55 | to a profit |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q1 2026Total $56.4M (+1096%)
Single Reportable grew +99% year on year
Segment Latestquarter on quarteryear on year
- Single Reportable$56.4M$56.4MQoQ +1096%year on year +99%+1096%+99%